Oslo  (Norway), 9 May 2022 - PCI Biotech (OSE: PCIB), a clinical-stage biopharma
company  developing  innovative  therapeutics  that  address  significant  unmet
medical  needs in cancer today announced a  poster presentation at the TIDES USA
2022 conference, a hybrid on-site and virtual event taking place May 9-12, 2022
in Boston, USA.

Dr.  Anders  Høgset,  CSO,  will  on-site  present a poster named 'Photochemical
internalisation  (PCI)  -  enhanced  and  site-directed  mRNA delivery by light-
induced  endosomal  release'  giving  an  overview  of PCI Biotech's proprietary
platform  technology for use in the  exciting field of mRNA-based therapies. The
poster    will    be   made   available   on   PCI   Biotech's   webpage   under
www.pcibiotech.no/other-presentations           (http://www.pcibiotech.no/other-
presentations).

Contact information:
Per Walday, CEO
pw@pcibiotech.no (mailto:pw@pcibiotech.no)
Mobile: +47 917 93 429

About TIDES USA 2022
TIDES  USA is an  oligonucleotide and peptide  therapeutics focused event. It is
the   world's   largest   gathering   for   those   interested  in  accelerating
oligonucleotide,  peptide, mRNA and genome editing products from early discovery
to late-stage development and commercialisation.

The  program features concurrent tracks covering scientific themes including in-
depth  development  strategies,  trends,  and  technologies  across  the  entire
spectrum  of  oligonucleotides,  peptides,  mRNA,  and genome editing. Industry-
leading  speakers share cutting-edge science  and progress and scientific agenda
includes 150+ of the industry's top scientists to present the latest science and
industry  updates  across  the  entire  spectrum  from  discovery,  preclinical,
clinical   development  through  CMC,  manufacturing  and  commercialisation  of
therapeutics  and  vaccines  for  oligos,  peptides,  mRNA  and  genome  editing
products.

About PCI Biotech
PCI  Biotech is a biopharmaceutical  clinical stage development company focusing
on  development and  commercialisation of  novel therapies  for the treatment of
cancer  through  its  innovative  photochemical internalisation (PCI) technology
platform.  PCI induces  triggered endosomal  release that  is used to unlock the
true potential of therapeutic modalities.

The  company's lead programme fimaVacc aims  to enhance immunotherapy in cancer,
by  triggered endosomal release of antigens  or nucleic acids encoding antigens,
or  immunostimulatory  factors.  Enhancement  of  relevant immune responses with
protein-  and peptide-based  vaccines were  successfully demonstrated  in humans
through an extensive Phase I study in healthy volunteers and a Phase II study is
in  planning  with  the  aim  to  demonstrate  enhancement  of immunotherapy for
treatment  of  solid  tumours.  In  the  fimaNAc  programme endosomal release is
utilised  to provide intracellular  delivery of nucleic  acids, such as mRNA and
RNAi  therapeutics, thereby addressing one of  the major bottlenecks facing this
emerging and promising field.

For      further      information,      please     visit:     www.pcibiotech.com
(http://www.pcibiotech.com)

Forward-looking statements
This  announcement may contain forward-looking statements, which as such are not
historical  facts, but  are based  upon various  assumptions, many  of which are
based,  in  turn,  upon  further  assumptions.  These assumptions are inherently
subject  to  significant  known  and  unknown  risks,  uncertainties  and  other
important  factors. Such risks, uncertainties, contingencies and other important
factors  could cause  actual events  to differ  materially from the expectations
expressed  or implied in  this announcement by  such forward-looking statements.
PCI  Biotech disclaims  any obligation  to update  or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.